Collegium Pharmaceutical (COLL) Long-Term Deferred Tax (2014 - 2026)

Collegium Pharmaceutical's Long-Term Deferred Tax history runs 8 years deep, the most recent figure standing at $113.6 million for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 23.89% year-over-year to $113.6 million in Q1 2026; TTM through Mar 2026 was $113.6 million, a 23.89% increase from a year earlier, with the FY2025 full-year figure at $112.5 million, up 14.8% from the prior year.
• Long-Term Deferred Tax climbed to $113.6 million in Q1 2026 per COLL's latest filing, from $112.5 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $113.6 million in Q1 2026 and bottomed at $24.0 million in Q4 2022.
• The 5-year median for Long-Term Deferred Tax is $30.7 million (2024), against an average of $56.0 million.
• Across the five-year window, Long-Term Deferred Tax slumped 69.31% in 2022 and surged 273.33% in 2024, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $24.0 million in 2022, then grew by 9.64% to $26.3 million in 2023, then jumped by 273.33% to $98.0 million in 2024, then gained by 14.8% to $112.5 million in 2025, then climbed by 0.91% to $113.6 million in 2026.
• Per Business Quant, the three latest COLL Long-Term Deferred Tax figures stand at $113.6 million (Q1 2026), $112.5 million (Q4 2025), and $102.5 million (Q3 2025).